Wednesday, October 16, 2024
11:00AM – 12:00PM ET
Please note this TeleECHO program is 11:00AM Eastern, 10:00AM Central, 9:00AM Mountain and 8:00AM Pacific.
PRESENTING FACULTY
 |
Matthew S. Davids, MD, MMSc Director of Clinical Research Division of Lymphoma Dana-Farber Cancer Institute Associate Professor of Medicine Harvard Medical School Boston, MA |
PROGRAM OVERVIEW
This educational activity is designed for oncologists, hematologists, nurse practitioners, pharmacists, and other multidisciplinary oncology care team members that are involved in the management of patients with chronic lymphocytic lymphoma (CLL). Specifically, the program will help HCPs assess the safety, efficacy, and mechanisms of action of novel and upcoming CLL treatments. This will aid in managing their patients with CLL by differentiating the safety and effectiveness of established and innovative BTK inhibitors, understanding the adverse events specifically associated with these inhibitors, and how to how to manage them. Finally, the program will introduce various favored and substitute treatment options that can be utilized in the management of various stages of CLL.
TARGET AUDIENCE
This activity is designed to meet the educational needs of medical oncologists, hematologists, nurse practitioners, pharmacists, and other multidisciplinary oncology care team members.
LEARNING OBJECTIVES
Upon the completion of this program, attendees should be able to:
- Summarize the safety, effectiveness, and ways of functioning of novel and upcoming treatments for individuals diagnosed with CLL
- Examine and differentiate the effectiveness and safety profiles of both established and innovative BTK inhibitors utilized for managing CLL
- Provide an overview of the prevalent adverse effects associated with BTK inhibitors employed in the therapy of CLL, as well as their corresponding management strategies
- Present a summary of the favored and substitute treatment choices for varying stages of therapy in the management of CLL
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education (CE) for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this virtually live activity for a maximum of 1.25 AMA PRA Category 1 CreditsTM. Physicians should claim only the credit commensurate with the extent of their participation in the virtually live activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.25 ANCC contact hours.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education (ACCME) Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG-sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During this lecture, the faculty may mention the use of medications for both FDA-approved and non-approved indications.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are science-based.
This activity is designed for educational purposes. Participants have a responsibility to use this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
